Pharma in silica

The novel silica-based nanocarrier OpKemo™ promises enhanced therapeutic value for the treatment of most solid tumours without a dramatic increase in costs, hence ensuring a wide market access potential.

The versatility of silica’s chemistry is likely to grant OpKemo™ drug distinctive advantages over established nanomedicines such as liposomes and protein-linked drugs.

A silica sphere can be engineered for single or multiple-drug administration, optimal nano or micro size, simple and safe formulation, leakage-free and long-duration circulation, high-tumour selectivity and environment-triggered, tuneable release. Each vehicle is designed to suit the drug cargo and the cancer it treats. The resulting solution is scalable under GMP, cost-effective and patentable.

Pharma in silica currently develops safer versions of off-patent cytotoxic agents such as paclitaxel. Other development opportunities will be pursued via out-licensing, partnering and project-specific financing.